Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Common Equity: 2010-2024

Historic Common Equity for OptimizeRx (OPRX) over the last 15 years, with FY2024 value amounting to $117.0 million.

  • OptimizeRx's Common Equity rose 681.26% to $122.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $122.3 million, marking a year-over-year increase of 681.26%. This contributed to the annual value of $117.0 million for FY2024, which is 755.02% down from last year.
  • Latest data reveals that OptimizeRx reported Common Equity of $117.0 million as of FY2024, which was down 755.02% from $126.6 million recorded in FY2023.
  • In the past 5 years, OptimizeRx's Common Equity registered a high of $131.4 million during FY2021, and its lowest value of $50.0 million during FY2020.
  • In the last 5 years, OptimizeRx's Common Equity had a median value of $126.1 million in 2022 and averaged $110.2 million.
  • As far as peak fluctuations go, OptimizeRx's Common Equity soared by 16289.66% in 2021, and later tumbled by 755.02% in 2024.
  • Annual analysis of 5 years shows OptimizeRx's Common Equity stood at $50.0 million in 2020, then skyrocketed by 162.9% to $131.4 million in 2021, then dropped by 4.01% to $126.1 million in 2022, then rose by 0.35% to $126.6 million in 2023, then dropped by 7.55% to $117.0 million in 2024.
  • Its Common Equity stands at $117.0 million for FY2024, versus $126.6 million for FY2023 and $126.1 million for FY2022.